![](http://www.thielerlaw.com/assets/news/UxXo6u9z_download.png)
Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Myriad Genetics Inc (NASDAQ: MYGN) violated securities laws in connection with certain financial statements.
The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Myriad Genetics Inc (NASDAQ: MYGN) concerning whether a series of statements by Myriad Genetics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On August 13, 2019, the Company issued its fourth quarter and full year results for 2019, reporting that revenue in the fourth quarter was 2% below expectations largely due to lower reimbursement for its expanded carrier screening test. During a conference call with investors, Bryan Riggsbee, Myriad’s Chief Financial Officer, also revealed that “the FDA requested changes to the GeneSight [Psychotropic] test offering” and that Myriad has “been in ongoing discussions with the FDA regarding its request.”
Following this news, NASDAQ: MYGN fell 42.76%, to close at $25.50 on August 14, 2019.
Based in Salt Lake City, Utah, and founded in 1991 Myriad Genetics Inc develops and markets predictive, personalized, and prognostic medicine tests worldwide.
If you purchased shares of Myriad Genetics Inc (NASDAQ: MYGN) on or before August 13, 2019, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.
Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.
Thieler Law Corp
2534 State Street - Suite 406,
San Diego, CA 92101
by
email: mail@thielerlaw.com
or
telephone at +1 (619) 377 - 4324
or
visit our website http://www.thielerlaw.com/
or
Facsimile: +1 (619) 785 – 3185